Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Thomas J GeorgeAzka AliYu WangJi-Hyun LeeAlison M IveyDavid L DeRemerKaren C DailyCarmen J AllegraSteven J HughesZ Hugh FanMiles E CameronAndrew R JudgeJose G TrevinoPublished in: The oncologist (2021)
The addition of dasatinib did not appear to add incremental clinical benefit to FOLFOX in untreated patients with mPC.